Allos Therapeutics Earnings Cheat Sheet: Streak of Three Straight Losses Snapped

Allos Therapeutics, Inc. (NASDAQ:ALTH) reversed to a profit in the second quarter, beating Wall Street estimates. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer.

Investing Insights: Steve Jobs Prepares to Deliver a New Catalyst for Apple’s Stock >>

Allos Therapeutics Earnings Cheat Sheet for the Second Quarter

Results: Swung to a profit of $2.2 million (2 cents per diluted share) in the quarter. The drug manufacturer had a net loss of $20 million or a loss of 19 cents per share in the year earlier quarter.

Revenue: Rose more than fourfold to $39.1 million from the year earlier quarter.

Actual vs. Wall St. Expectations: ALTH beat the mean analyst estimate of a loss of 14 cents per share. It beat the average revenue estimate of $11.9 million.

Quoting Management: President and Chief Executive Officer Paul L. Berns stated, “Along with growing U.S. sales of FOLOTYN for relapsed or refractory PTCL, our key objectives for the remainder of the year are to advance our global registration programs for FOLOTYN in first line PTCL and relapsed or refractory CTCL, and to expand the commercial potential of FOLOTYN outside the U.S. by pursuing regulatory approval in the EU, which may occur in early 2012.”

Key Stats:

The company has now topped analyst estimates for the last four quarters. It beat the mark by one cent in the first quarter, by one cent in the fourth quarter of the last fiscal year, and by 2 cents in the third quarter of the last fiscal year.

ALTH’s profit in the latest quarter follows losses in the three previous quarters. The company reported a net loss of $15.2 million in the first quarter, a loss of $18.1 million in the fourth quarter of the last fiscal year and a loss of $18.8 million in the third of the last fiscal year.

Competitors to Watch: Seattle Genetics, Inc. (NASDAQ:SGEN), Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Hospira, Inc. (NYSE:HSP), Mylan Inc. (NASDAQ:MYL), Cell Therapeutics, Inc. (NASDAQ:CTIC), Cephalon, Inc. (NASDAQ:CEPH), Accentia Biopharmaceuticals, Inc (ABPI), Celgene Corporation (NASDAQ:CELG), Biogen Idec Inc. (NASDAQ:BIIB), and Genta Incorporated (GNTA).

Investing Insights: Steve Jobs Prepares to Deliver a New Catalyst for Apple’s Stock >>

(Source: Xignite Financials)